Literature DB >> 22405569

Oncologists' assessments of lung cancer patient and family disagreements regarding treatment decision making.

Laura A Siminoff1, Lindsey Dorflinger, Amma Agyemang, Sherman Baker, Maureen Wilson-Genderson.   

Abstract

BACKGROUND: Disagreements between cancer patients and their caregivers about treatment and care can affect the patient's physical and mental well-being. Therefore it is important to understand if oncologists can accurately identify the presence of patient-caregiver decisional conflict. This study examined assessments made by lung cancer patients, their caregivers, and their oncologists regarding patient-caregiver disagreements concerning treatment and care decisions. PARTICIPANTS AND METHODS: We assessed the extent to which the patient, caregiver, and oncologist reported disagreement between the patient and the family member regarding treatment decisions in 134 patient-caregiver-oncologist triads. Descriptive statistics were used to explore rates of concordance amongst all possible combinations of raters. Loglinear models were tested for 3-way agreement.
RESULTS: Most patient-caregiver pairs, 82.1% (n = 110), reported agreement concerning presence or absence of decisional conflict. Oncologists were more successful in detecting absence of conflict than the presence of conflict. When the caregiver and the oncologist agreed, it was regarding the absence of conflict (64.9%), rather than the presence of conflict. In 10.6% (n = 15) of cases, oncologists reported that conflictual relationships negatively impacted their ability to provide patient care.
CONCLUSIONS: Recent models of cancer patient care promote including the caregiver fully in the process while respecting the primacy of the patient's perspective. However, these models assume that the oncologist will recognize when disagreements exist and be able to assist in conflict resolution. The degree to which the oncologist identified that conflict exists and implications for their ability to provide patient care when familial disagreements existed are discussed.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22405569      PMCID: PMC3368070          DOI: 10.1016/j.lungcan.2012.02.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  26 in total

1.  Measuring discord in treatment decision-making; progress toward development of a cancer communication and decision-making assessment tool.

Authors:  Laura A Siminoff; Julia H Rose; Amy Zhang; Stephen J Zyzanski
Journal:  Psychooncology       Date:  2006-06       Impact factor: 3.894

2.  Oncologists' recognition of depression in their patients with cancer.

Authors:  S D Passik; W Dugan; M V McDonald; B Rosenfeld; D E Theobald; S Edgerton
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it.

Authors:  D Rothenbacher; M P Lutz; F Porzsolt
Journal:  Eur J Cancer       Date:  1997-07       Impact factor: 9.162

4.  Dealing with conflict in caring for the seriously ill: "it was just out of the question".

Authors:  Anthony L Back; Robert M Arnold
Journal:  JAMA       Date:  2005-03-16       Impact factor: 56.272

5.  Social constraints and spousal communication in lung cancer.

Authors:  Hoda Badr; Cindy L Carmack Taylor
Journal:  Psychooncology       Date:  2006-08       Impact factor: 3.894

6.  Patient preferences for medical decision making: who really wants to participate?

Authors:  N K Arora; C A McHorney
Journal:  Med Care       Date:  2000-03       Impact factor: 2.983

7.  Patients and carer experiences of care provision after a diagnosis of lung cancer in Scotland.

Authors:  Meinir Krishnasamy; Mary Wells; Erna Wilkie
Journal:  Support Care Cancer       Date:  2006-09-02       Impact factor: 3.603

8.  Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions.

Authors:  Elena B Elkin; Susie H M Kim; Ephraim S Casper; David W Kissane; Deborah Schrag
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

9.  How well do medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems? Data from a survey of five oncologists.

Authors:  S Newell; R W Sanson-Fisher; A Girgis; A Bonaventura
Journal:  Cancer       Date:  1998-10-15       Impact factor: 6.860

10.  Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer.

Authors:  Da-Tong Chu; Sang-We Kim; Han-Pin Kuo; Rifat Ozacar; Frantisek Salajka; S Krishnamurthy; Danail Damyanov; Sedat Altug; William H H Reece; Li Wang
Journal:  Lung Cancer       Date:  2007-03-07       Impact factor: 5.705

View more
  4 in total

1.  Dyadic Perceptions of the Decision Process in Families Living With Lung Cancer.

Authors:  Lyndsey M Miller; Donald R Sullivan; Karen S Lyons
Journal:  Oncol Nurs Forum       Date:  2017-01-01       Impact factor: 2.172

Review 2.  Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.

Authors:  Graham W Warren; Kenneth D Ward
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  What is a good medical decision? A research agenda guided by perspectives from multiple stakeholders.

Authors:  Jada G Hamilton; Sarah E Lillie; Dana L Alden; Laura Scherer; Megan Oser; Christine Rini; Miho Tanaka; John Baleix; Mikki Brewster; Simon Craddock Lee; Mary K Goldstein; Robert M Jacobson; Ronald E Myers; Brian J Zikmund-Fisher; Erika A Waters
Journal:  J Behav Med       Date:  2016-08-26

4.  "In Eight Minutes We Talked More About Our Goals, Relationship, Than We Have in Years": A Pilot of Patient-Caregiver Discussions in a Neuro-Oncology Clinic.

Authors:  Dana Ketcher; Lee Ellington; Brian R W Baucom; Margaret F Clayton; Maija Reblin
Journal:  J Fam Nurs       Date:  2020-05       Impact factor: 2.680

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.